Home
  • Health & Wellness
  • Conditions
  • Insurance & Money

Watson Receives FDA Approval For Generic Combunox

Home » Personal Health » Prescription Drugs

All About:
  • Prescription Drugs

Submitted by hareyan on Nov 28th, 2007
Posted under:
  • Prescription Drugs

Watson Pharmaceuticals has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride and Ibuprofen Tablets (CII) in the 5 mg/400 mg strength.

Watson's Oxycodone Hydrochloride and Ibuprofen product is the generic equivalent to Forest Laboratories Inc.'s Combunox, which is indicated for the short-term (not more than 7 days) management of acute, moderate to severe pain.

For the 12-months ending September 2007, Combunox had total U.S. sales of approximately $4 million, according to IMS Health data. Watson intends to launch its Oxycodone Hydrochloride and Ibuprofen product immediately.

Source: 
Watson Pharmaceuticals, Inc.
  • Login or register to post comments
Write For EmaxHealth

Similar Stories

  • Mental Health Problems Linked To Chantix, Zyban
  • Biological Warfare In Bacteria - Hope For New Antibiotics
  • Radioactive Substances Go Missing
  • Piroxicam No Longer Used For Acute Pain, Inflammation
  • Antibiotics Take Toll On Beneficial Gut Microbes

Enter your email address:

 Subscribe in a reader
  • ETHEX Recalls Morphine Tablets
  • FDA Announces New Labeling Changes For Regranex
  • Overwhelming Support For Follow-On Biologics To Reduce Drug Cost
  • FreshFx In Scalder Reduces Pathogens In Evisceration
  • Drug Mega-Doses May Induce Side Effects
  • FDA Approves Carbinoxamine Maleate Tablet
  • FDA Approves Potassium Chloride Extended-Release Capsules
  • Privacy Policy
  • Disclaimer
  • About Us
  • Editorial Review Process
  • Advertise
  • Contact
  • Contributors
  • Health RSS Feeds